Cargando…

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma

Detalles Bibliográficos
Autores principales:	Liberatore, Carmine, Perini, Tommaso, Passeri, Cecilia, Ferla, Valeria, Fioritoni, Francesca, Girlando, Virginia, Iuliani, Ornella, Orsini, Alessia, Montanaro, Guido, Farina, Francesca, Di Nicola, Alessandro, Nitti, Rosamaria, Pulini, Stefano, Mastaglio, Sara, Santarone, Stella, Coppola, Milena, Marktel, Sarah, Accorsi, Patrizia, Ciceri, Fabio, Marcatti, Magda, Ianni, Mauro Di
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690897/ https://www.ncbi.nlm.nih.gov/pubmed/37439346 http://dx.doi.org/10.3324/haematol.2023.283452

Ejemplares similares

P24 HIGH-DOSE CYCLOPHOSPHAMIDE 4 GR/M2 AND STEM-CELL COLLECTION AFTER DARATUMUMAB-BASED QUADRUPLET INDUCTION IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER EXPERIENCE
por: Liberatore, C., et al.
Publicado: (2023)

P965: STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M2 ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA
por: Perini, Tommaso, et al.
Publicado: (2023)

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia
por: Liberatore, Carmine, et al.
Publicado: (2023)

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
por: Farina, Francesca, et al.
Publicado: (2022)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study
por: Xue, Elisabetta, et al.
Publicado: (2022)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS
por: Farina, Francesca, et al.
Publicado: (2023)

P62 USE OF ANTIVIRAL FOR PAUCISINTOMATIC COVID-19 INFECTION IN MULTIPLE MYELOMA PATIENTS UNDERGOING TREATMENT
por: Annibali, O., et al.
Publicado: (2023)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients
por: Serpenti, Fabio, et al.
Publicado: (2021)

P1549: HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.
por: Farina, Francesca, et al.
Publicado: (2023)

Homocysteine and education but not lipoprotein (a) predict estimated 10-year risk of cardiovascular disease in blood donors: a community based cross-sectional study
por: Vadini, Francesco, et al.
Publicado: (2019)

Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis
por: Ardizzoia, Federica, et al.
Publicado: (2022)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2021)

Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review
por: Steffanoni, Sara, et al.
Publicado: (2023)

Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation
por: Liberatore, Carmine, et al.
Publicado: (2023)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Efficacy of daratumumab in refractory primary Sjögren disease
por: Nocturne, Gaetane, et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

NOTCH and Graft-Versus-Host Disease
por: Di Ianni, Mauro, et al.
Publicado: (2018)

Fatigue as Mediator Factor in PTSD-Symptoms after Allogeneic Hematopoietic Stem Cell Transplantation
por: Di Francesco, Giulia, et al.
Publicado: (2023)

Improving the safety of cell therapy with the TK-suicide gene
por: Greco, Raffaella, et al.
Publicado: (2015)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Dr. James A. S. Grant (Grant-Bey)
Publicado: (1896)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB
por: Clerici, Daniela, et al.
Publicado: (2022)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Memorandum - external grants and contract award (ERC grants)
por: Granier, Cecile
Publicado: (2019)

Daratumumab in the treatment of C3 glomerulopathy with monoclonal gammopathy: a case report and literature review
por: Esposito, Pasquale, et al.
Publicado: (2023)

94 Evaluation of a grant writing workshop designed to increase submission and award rates for career development awards
por: Ianni, Phillip, et al.
Publicado: (2023)

Daratumumab-induced transient myopic shift
por: Mavrommatis, Maria A., et al.
Publicado: (2018)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Daratumumab for immune thrombotic thrombocytopenic purpura
por: van den Berg, Jana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n2c1lnip8o50sm0u8utddi7fid